linjc16/ctgov huggingface dataset:
Clinical Evaluation of the CADenceTM System in Detection of Coronary Artery Diseases

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to evaluate the effectiveness of the CADence system, a non-invasive device, in detecting greater than or equal to 50% coronary stenosis anywhere in the coronary tree.

Official Title
-----------------
Clinical Evaluation of the CADence System in Detection of Coronary Artery Diseases

Conditions
-----------------
Coronary Artery Disease

Intervention / Treatment
-----------------
* Device: CADence System


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Over 18 years old Willing and able to give informed consent Indicated for angiography evaluation. Exclusion Criteria: Pregnant or nursing Presence of pacemaker/defibrillator Presence of artificial valve Presence of severe valve disease Presence of congenital heart defect Left Ventricular Assist Device (LVAD) Presence of a bypass graft Presence of scars on the site thorax areas Coarctation of the aorta Participation in trial within 30 days prior to collecting CADenceTM data Asthma with wheezing Inability to lie flat in the supine position Acute STEMI Heart Transplant Recent Cocaine Use

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: CADence System|Non-invasive detection of > or equal to 50% stenosis in any of the major coronary arteries.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy of CADence in detecting greater than or equal to 50% stenosis anywhere in the coronary tree. | The CADence System will be considered to have demonstrated effectiveness in detecting greater than or equal to 50% coronary artery stenosis anywhere in the coronary tree if the estimated sensitivity as compared to angiography is statistically higher than 70%. | within three months |
Develop and Implement Asthma Controlling Strategies

Study Overview
=================
Brief Summary
-----------------
To develop and implement asthma-controlling educational strategies for inner city and high risk populations.

Detailed Description
-----------------
BACKGROUND: Asthma is a serious chronic disease affecting about 12 million Americans; about 3 million are children. The study was part of an initiative, Developing and Implementing at the State and Local Level Educational Strategies and Interventions for Controlling Asthma in Inner City and High Risk Populations, released in February 1993 by the National Asthma Education Program of the Office of Prevention, Education and Control. DESIGN NARRATIVE: A computer-assisted multimedia instructional and feedback system, Asthma Patient/Provider Partnership System (APPPS), was developed for African American and Hispanic school-age children that was suited for adoption and implementation in clinical and other settings based on the National Asthma Education Program's Expert Panel Guidelines on the Diagnosis and Management of Asthma. A formative evaluation of the educational intervention was conducted. Also, an efficacy study of the intervention in three clinical settings was conducted and the findings of this study were incorporated into the APPPS. Finally, a recommended dissemination strategy was prepared for diffusion of the system to other settings.

Conditions
-----------------
Asthma, Lung Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
No eligibility criteria

Ages Eligible for Study
-----------------
Minimum Age: 0 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Molecular Analysis Of Bladder Cancer

Study Overview
=================
Brief Summary
-----------------
This is a laboratory study where the investigators hope to look at chromosomal events implicated in bladder cancer.

Official Title
-----------------
Molecular Analysis Of Bladder Cancer

Conditions
-----------------
Bladder Cancer, Bladder Neoplasms

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Bladder cancer

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Bladder Cancer, Cancer, bladder, Urinary Bladder Cancer
DOCICAR: Cardiac Dysfunction in Cirrhosis

Study Overview
=================
Brief Summary
-----------------
Patients with cirrhosis have a altered cardiac response to stress. This study evaluate the cardiac response by MRI during dobutamine stress. Hypothesis: impared increase in cardiac output, cardiac index, ejection fraction.

Official Title
-----------------
Cardiac Dysfunction in Cirrhosis: Cirrhotic Cardiomyopathy Evaluated by Dobutamin MRI.

Conditions
-----------------
Cirrhosis, Cirrhotic Cardiomyopathy

Intervention / Treatment
-----------------
* Drug: Dobutamine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Non alkoholic cirrhosis Exclusion Criteria: Coma hepaticum Primary cardiac diseases

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Dobutamine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Effects of Continuous Passive Motion on the Spinal Circuitries and Its Adaptation in Patients With Spasticity Resulting From Upper Motor Neuron Lesions

Study Overview
=================
Brief Summary
-----------------
In animal and human studies, histochemical and physiological evidences showed that the muscle transferred from slow, fatigue-resistant muscle to fast, fatigable muscle after spinal cord injury. The alternation of muscular property was accompanied by the alternation of spinal circuitry property, and was related to the immobilization adaptation. Previous study showed that remobilization by continuous passive motion (CPM) for one month would restore the function of spinal circuitry in individual with chronic SCI. It is possible that long term application of CPM can reverse the adaptation of contractile properties of the paralyzed muscle after SCI. The purpose of this study is to investigate the effect of a four month CPM training on muscular properties in individuals with chronic SCI.

Conditions
-----------------
Spinal Cord Injury(SCI)

Intervention / Treatment
-----------------
* Procedure: Ankle continuous passive motion machine.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of complete spinal cord injury

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: SCI<br>SCI participated in a 4-month robot-assisted passive ankle exercise regimen. | Procedure: Ankle continuous passive motion machine.<br>* A rehabilitation program of machine driven passive stretch exercise on ankle.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The contractile properties of the muscles | Measure of changes in contractile properties of soleus and tibialis anterior | Baseline, 1 month, 2 months, 3 months, and 4 months | 
| Fatigue index | Measure of changes in Fatigue index of soleus and tibialis anterior. | Baseline, 1 month, 2 months, 3 months, and 4 months | 
| Clinical muscle tone tests | Measure of changes in clinical muscle tone tests of soleus and tibialis anterior by Modified Ashworth Scale. | Baseline, 1 month, 2 months, 3 months, and 4 months | 
| Patient Reported Impact of Spasticity Measure (PRISM) | Measure of changes in PRISM. | Baseline, 1 month, 2 months, 3 months, and 4 months | 
| The potential adverse effects of ankle swelling | Measure of changes in the potential adverse effects of ankle swelling. | Baseline, 1 month, 2 months, 3 months, and 4 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Spinal cord injury, Passive motion, Fatigue index, Hypertonia
A Multi-center Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on Non-head Locations (Trunk and Extremities)

Study Overview
=================
Brief Summary
-----------------
The open label study is designed to assess the safety and efficacy of 0.05% PEP005 Gel when applied to an area of skin containing 4-8 AK lesions on non-head locations.

Official Title
-----------------
A Multi-center, Open-label Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, 0.05% in Patients With Actinic Keratoses on Non-head Locations (Trunk and Extremities)

Conditions
-----------------
Actinic Keratosis

Intervention / Treatment
-----------------
* Drug: PEP005 Gel


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient is male or female and at least 18 years of age. Female patient must be of either: Non-childbearing potential, post-menopausal, or there is a confirmed clinical history of sterility (e.g., the patient is without a uterus) Childbearing potential, provided there are negative urine pregnancy test results prior to study treatment, to rule out pregnancy Exclusion Criteria Cosmetic or therapeutic procedures within two weeks and within 2 cm of the selected treatment area. Treatment with immunomodulators, interferon/ interferon inducers or systemic medications that suppress the immune system within 4 weeks. Treatment with 5-FU, imiquimod, diclofenac, or photodynamic therapy: within 8 weeks and 2 cm of the selected treatment area.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: PEP005 gel<br>PEP005 gel, 0.05% administered once daily for 2 consecutive days | Drug: PEP005 Gel<br>* 0.05% two day treatment<br>* Other names: PEP005;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety (Incidence of treatment related AEs, local skin reactions and pigmentation and scarring) |  | 57 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy (complete and partial clearance of AK lesions) |  | 57 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Peplin, Actinic keratosis, PEP005
Diagnostic Value of D-dimer/Fibrinogen Ratio in Patients With Acute Aortic Dissection

Study Overview
=================
Brief Summary
-----------------
Acute aortic dissection is rare but potentially life-threatening disease with an incidence of 5-30 cases per million, annually. Therefore prompt diagnosis is crucial. D-dimer values have been shown to be useful in the diagnosis of acute aortic dissection. Fibrinogen levels have been shown to be low, normal or high in individuals with acute aortic dissection. This study aims to investigate whether D-dimer/fibrinogen ratio can be valuable for diagnosis of acute aortic dissection.

Official Title
-----------------
Diagnostic Value of D-dimer/Fibrinogen Ratio in Patients With Acute Aortic Dissection

Conditions
-----------------
Aortic Dissection, Pulmonary Embolism

Intervention / Treatment
-----------------
* Diagnostic Test: D-dimer/fibrinogen ratio


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of acute aortic dissection Diagnosis of acute pulmonary embolism Diagnosis of non-cardiac chest pain Exclusion Criteria: Any etiology of chest pain other than acute aortic dissection, acute pulmonary embolism, or non-cardiac chest pain Participants who do not give consent for enrollment

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Acute aortic dissection<br>Patients with a diagnosis of acute aortic dissection. | Diagnostic Test: D-dimer/fibrinogen ratio<br>* The ratio of D-dimer (ng/ml) to fibrinogen (mg/dl)<br>|
| Acute pulmonary embolism<br>Patients with a diagnosis of acute pulmonary embolism | Diagnostic Test: D-dimer/fibrinogen ratio<br>* The ratio of D-dimer (ng/ml) to fibrinogen (mg/dl)<br>|
| Non-cardiac chest pain<br>Patients with non-cardiac chest pain | Diagnostic Test: D-dimer/fibrinogen ratio<br>* The ratio of D-dimer (ng/ml) to fibrinogen (mg/dl)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Acute aortic dissection | Diagnosis of acute aortic dissection confirmed by contrast enhanced computed tomography, magnetic resonance imaging, echocardiography or aortography | 24 hours |
The Effects of Morphine on Desflurane Consumption and Recovery Time

Study Overview
=================
Brief Summary
-----------------
Combination of volatile and opioid agents are used to achieve unconsciousness, haemodynamic stability and analgesia for surgical prosedures. This prospective, randomized, double-blind, controlled study evaluates the effects of two different doses of morphine sulphate (0.1 mg/kg and 0.2 mg/kg), on desflurane consumption, recovery characteristics, postoperative analgesic requirements and side effects during total abdominal hysterectomy.

Official Title
-----------------
Comparison of Two Different Doses of Intravenous Morphine on Desflurane Consumption and Recovery Time in Patients Undergoing Total Abdominal Hysterectomy

Conditions
-----------------
Abdominal Hysterectomy (& Wertheim)

Intervention / Treatment
-----------------
* Drug: Morphine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: undergoing total abdominal hysterectomy with general anaesthesia Exclusion Criteria: renal dysfunction (cre>1.2), liver failure, cardiovascular, psychiatric, allergic and metabolic disorders

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Group Saline<br>Group Saline (Group S) received i.v saline 0.9 % in 10 ml volume (n=30) | Drug: Morphine<br>* Group Saline (Group S): Received i.v saline 0.9 % in 10 ml volume (n=30) Group Morphine 1 (Group M1): Received i.v morphine 0.1 mg kg-1 in 10 ml volume (n=30) Group Morphine 2 (Group M2): Received i.v morphine 0.2 mg kg-1 in 10 ml volume (n=30)<br>|
| Active Comparator: Group Morphine 1<br>Group Morphine 1 (Group M1) received i.v morphine 0.1 mg kg-1, in 10 ml volume (n=30) | Drug: Morphine<br>* Group Saline (Group S): Received i.v saline 0.9 % in 10 ml volume (n=30) Group Morphine 1 (Group M1): Received i.v morphine 0.1 mg kg-1 in 10 ml volume (n=30) Group Morphine 2 (Group M2): Received i.v morphine 0.2 mg kg-1 in 10 ml volume (n=30)<br>|
| Active Comparator: Group Morphine 2<br>Group Morphine 2 (Group M2) received i.v morphine 0.2 mg kg-1, in 10 ml volume (n=30) | Drug: Morphine<br>* Group Saline (Group S): Received i.v saline 0.9 % in 10 ml volume (n=30) Group Morphine 1 (Group M1): Received i.v morphine 0.1 mg kg-1 in 10 ml volume (n=30) Group Morphine 2 (Group M2): Received i.v morphine 0.2 mg kg-1 in 10 ml volume (n=30)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| postoperative desflurane consumption |  | postoperative first hour | 
| sedation scores for OASS scale |  | postoperative first hour |
Multimodal Imaging in Central Serous Chorioretinopathy

Study Overview
=================
Brief Summary
-----------------
This study aims to assess the contribution of the multimodal imaging, combining a routine examination using Optical Coherence Tomography (OCT) with an imaging procedure using adaptive optics retinal camera. This is a feasibility study with a limited number of patients.

Conditions
-----------------
Central Serous Chorioretinopathy

Intervention / Treatment
-----------------
* Device: RTX1 IMAGIN EYE retinal camera


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Signed informed consent form Beneficiary/affiliated to French social security/social healthcare Active ou chronic Central Serous Chorioretinopathy on at least one eye Absence of other known ophthalmological pathology or of any ophthalmological conditions revealed during the examination Exclusion Criteria: Legal incapacity or limited legal capacity Predictable poor adherence Subject without health insurance Pregnant or breatfeeding women Sujet étant dans la période d'exclusion d'une autre étude ou prévue par le fichier national des volontaires Presence of transparent medium opacity damaging images quality Previous photosensitivity Recent treatment with PhotoDynamic Therapy (PDT) Use of drugs inducing photosensitivity

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Adaptative optics retinal camera<br> | Device: RTX1 IMAGIN EYE retinal camera<br>* In addition to the routine examination including OCT, an imaging using RTX1 IMAGIN EYE retinal camera will be performed.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Workability of images of RTX1 IMAGIN EYE retinal camera | Two readings of the images captured with adaptative optics retinal camera and assessment of their workability in routine care. | day 1 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Optical Coherence Tomography, Retinal camera
Psychological Symptoms in Patients With Behcet's Disease by SCL90-R

Study Overview
=================
Brief Summary
-----------------
To find the overall psychological profile of patients with Behcet's Disease (BD) and compare it with Non-BD patients.patients were checked for psychological symptoms by Symptom Check List 90 Revised (SCL90-R)

Detailed Description
-----------------
200 BD and 200 Non-BD patients were checked for psychological symptoms by Symptom Check List 90 Revised (SCL90-R). BD diagnosis was based on the new International Criteria for Behcet's Disease (ICBD). Non-BD patients were patients mimicking BD. All patients were asked to complete the SCL90-R when they attended the clinic for their routine follow-up. The demographic information and disease manifestations including ocular and neurological involvement were registered. For those with visual impairment, SCL90-R was applied by an interviewer. Frequencies and descriptive analysis were measured in both BD and Non-BD groups. Means and standard deviations (SD) of visual acuity were calculated. Data collected from SCL90-R did not have normal distribution in any dimension. The mean values of raw numbers, global severity index (GSI), the positive symptoms total (PST) and the positive symptom distress index (PSDI), were compared by Mann-Whitney U (M-W U) test.).To detect any bias in results due to data collection method, self reported data and reviewer collected data were compared.

Official Title
-----------------
Comparison of Psychological Symptoms in Patients With Behcet's Disease and Control Patients by Symptom Check List 90-Revised (SCL-90-R)

Conditions
-----------------
Behcet's Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Behcet's disease patients that their diagnosis was based on the new International Criteria for Behcet's Disease (ICBD). Non-Behcet's disease patients were patients mimicking BD. Exclusion Criteria: Probable Behcet's Disease

Ages Eligible for Study
-----------------
Minimum Age: 14 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Behcet's Disease patients that their diagnosis was based on the new International Criteria for Behcet's Disease (ICBD). | |
| 2<br>Non-Behcet's Disease patients were patients mimicking BD. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Total score of SCL90-R dimensions and global indexes |  | 22months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Psychological Symptoms, Behcet's Disease